Core Viewpoint - China Resources Pharmaceutical (华润医药) announced that its non-wholly owned subsidiary, Dong'e Ejiao (东阿阿胶), has decided to invest in and construct a health consumer goods industrial park, which will enhance its production capabilities and support the growth of its health consumer goods business [1][2]. Group 1: Investment and Construction Details - The health consumer goods industrial park is expected to include manufacturing facilities for health consumer products (such as pharmaceuticals, health foods, and functional foods), along with supporting warehousing, logistics facilities, quality inspection centers, new product incubation centers, and e-commerce sorting and finished product warehouses [1]. - The total area of the health consumer goods industrial park is approximately 406,800 square meters, with a proposed construction area of 151,100 square meters, which will include production facilities for Ejiao cakes, Ejiao dates, and Ejiao powder, as well as comprehensive warehouses and other storage facilities [1]. - The total investment for the project is estimated to be around RMB 1.485 billion, with fixed asset investment amounting to approximately RMB 1.421 billion and working capital of about RMB 64 million [1]. Group 2: Strategic Importance - The investment and construction of the health consumer goods industrial park is a necessary requirement for Dong'e Ejiao to implement its "1238" strategy, aiming to create a model for high-quality development in traditional Chinese medicine [2]. - The project is designed to establish a dual-driven business growth model combining pharmaceuticals and health consumer goods, fostering a second growth curve while addressing the urgent needs for the development of health consumer goods [2]. - The existing industrial park faces limitations in expansion and capacity bottlenecks, which hinder the ability to meet the rapid upgrades and iterations in health consumer goods, making the new construction essential for maintaining competitive advantages [2].

Core Insights - The Guangdong Province is set to enhance its traditional Chinese medicine (TCM) sector as part of the 14th Five-Year Plan, focusing on nine key areas of development [1][2] Group 1: Key Initiatives - Guangdong will strengthen digital empowerment and promote TCM standardization, including the implementation of TCM standards in the Greater Bay Area [1][2] - The province aims to deepen comprehensive reforms in TCM and advance the construction of national TCM reform demonstration zones, while promoting successful practices from the Sanming medical reform [1][2] - There will be an emphasis on integrating traditional Chinese and Western medicine, establishing a long-term collaborative mechanism, and supporting clinical cooperation projects for major diseases [1][2] Group 2: Talent Development and Industry Growth - Guangdong plans to build a robust TCM research and innovation matrix, accelerate the transformation of research results, and enhance the training of high-level TCM talent [2] - The province will promote the high-quality development of the entire TCM industry chain, strengthen source control and resource protection, and develop a traceability system for key local medicinal materials [2] - Efforts will be made to expand the cultural influence of TCM and enhance its global outreach, alongside a focus on medical ethics and safety production stability [2]

相关要求更强化了企业对药品安全与疗效的主体责任，倒逼企业补齐安全数据短板。唯有经得起科学审 视、市场检验，中药企业方能在变革中站稳脚跟。为此，企业需主动梳理品种，加强上市后研究，及时 修订说明书，切实守牢药品安全底线。 监管的新要求不是行业发展的"寒冬"，而是提质增效的"东风"。新规对药品说明书设置了刚性门槛，终 结了中成药批准文号"只进不出"的局面，淘汰安全风险不明的品种，以良性竞争倒逼产业从"数量扩 张"向"质量优先"转型。 中成药的规范化，不是单一环节的整治，而是全产业链的系统性重塑。从药品说明书修订，到价格规 范，再到饮片炮制标准完善，一系列监管举措形成合力，将推动中医药走向科学实证。这道"硬门槛"， 既守护百姓用药安全，激活行业发展动能，也将助力中医药行业更好服务全民健康。 近段时间，有关"大批中成药将被淘汰"的话题登上热搜，引发消费者关注。根据监管部门要求，经过3 年缓冲期后，2026年7月1日起，中成药说明书中禁忌、不良反应、注意事项仍标注"尚不明确"的，再注 册申请将依法不予通过。这对中成药标准化提出更高要求，既是对百姓用药安全的守护，也是推动中药 行业高质量发展的重要举措。 安全是用药的"生 ...

中药的价值不存在于"民族自豪"和"爱国叙事"里，而存在于临床效果和科学证据中。 近日，"大批中成药将退出市场"的消息引发关注。根据国家药监局《中药注册管理专门规定》第七十五 条相关规定，2026年7月1日之后，现存中成药在申请再注册时，其"中药说明书"的禁忌、不良反应、注 意事项中任何一项仍为"尚不明确"的，依法将不予再注册。媒体报道称，该规定将导致大量中成药因为 达不到要求而被淘汰，受影响的主要是"僵尸"批文品种，即徒有上市许可，却长期不生产不销售，缺乏 上市后药物警戒及不良反应监测数据的药品。 《2022国家中药监管蓝皮书》显示，我国目前有中成药生产企业约2400家，拥有中药品种9000余个，但 大量品种存在低水平重复、临床价值不明确等问题，批文数量与产业质量严重不匹配。国务院办公厅 2025年2月印发的《关于提升中药质量促进中医药产业高质量发展的意见》明确提出，逐步完善中成药 批准文号退出机制，指导改良一批，依法淘汰一批。实施中药再注册新规，是中药产业从"数量扩 张"向"质量优先"转型的必然选择，也是监管层推动中医药高质量发展的关键一步。 业内认为，对于尚未达到新规要求的中成药企业来说，接下来的选择无非 ...

记者丨唐唯珂 编辑丨季媛媛 中成药淘汰赛序幕拉开！大批中成药将退出市场。 距离2026年7月1日仅剩半年时间，国家药监局《中药注册管理专门规定》第七十五条的落地进入最后窗口期。 这一被业内称为中成药"生死条款"的规定明确，自2023年7月1日施行满三年起，说明书【禁忌】【不良反应】【注意事项】任意一项仍标 注"尚不明确"的中成药，再注册申请将依法不予通过。这意味着，国内现存约5.7万个中成药有效批准文号中，超70%存在安全信息标注问题的 批文将面临淘汰，一场由监管驱动的中药产业深度出清正式进入攻坚阶段。 此次监管新政的核心，是彻底终结中成药说明书长期以来的"尚不明确"时代，倒逼药品持有人补齐上市后安全数据短板。 中国食品药品监管杂志此前研究显示，2018年版《国家基本药物目录》中268个中成药品种的465份说明书里，不良反应、禁忌、药物相互作用 的标注率仅为20.64%、30.1%和1.07%，大量品种依靠模糊表述完成上市后的市场流通。而随着再注册大考临近，这种"模糊免责"的模式已彻 底失去生存空间。 图/图虫 国家药监局的监管动作已提前落地，2025年全年发布多批中成药说明书修订公告，活力苏口服液、固肾生发 ...

Group 1 - The board of directors of Yuanda Holdings approved the establishment of a traditional Chinese medicine (TCM) seed industry company, with a unanimous vote of 14 in favor [1] - The company will invest 81.25 million yuan through its wholly-owned subsidiary, Yuanda Biological Agriculture Co., Ltd., in collaboration with Gansu Hebo Long Medicine Technology Co., Ltd. and Professor Shao Baoping's team [1] - The new company will focus on three core areas: the creation of quality resources and biobreeding technology for TCM materials like Codonopsis pilosula and Astragalus membranaceus, the development of soilless seedling breeding technology, and the deep development and commercialization of TCM health products [1] Group 2 - Codonopsis pilosula is a key TCM material known for its ability to enhance energy and nourish the lungs, with a market sales forecast of approximately 8.5 billion yuan in 2024, and a total market size of 14.86 billion yuan when including the entire industry chain [2] - The market for Codonopsis pilosula is expected to grow at an annual rate of 9% to 12%, potentially exceeding 13.5 billion to 28 billion yuan by 2030 [2] - Astragalus membranaceus is recognized for its multiple health benefits, with a projected market sales of around 18.5 billion yuan in 2024, and a total market size of 30 billion yuan by 2030, growing at an annual rate of 8% to 10% [3] Group 3 - Yuanda Biological Agriculture Co., Ltd. has established a comprehensive strategic development plan since 2021, focusing on core agricultural inputs such as biopesticides and biofertilizers [3] - The company aims to provide integrated support for the production of high-end functional health foods, covering the entire process from quality resource creation to standard control in processing [3] - The collaboration represents the first industrial chain layout in the TCM field for Yuanda Holdings, leveraging biotechnological innovation to upgrade the traditional TCM industry [4]

Core Viewpoint - Guangdong Province is advancing the construction of a national traditional Chinese medicine (TCM) comprehensive reform demonstration zone, aiming for high-quality development in the TCM sector through the establishment of five key areas. Group 1: Medical High Ground - 14 hospitals have entered the top 100 in the national performance assessment of public TCM hospitals, with 80 specialties recognized as national advantageous specialties [1] - The total number of TCM outpatient services is projected to reach 252 million visits in 2024, accounting for 26.2% of the total outpatient visits in the province [1] Group 2: Innovation High Ground - A three-in-one innovation system comprising "key laboratories + innovation platforms + clinical transformation" has been established, with 16 TCM-related scientific achievements awarded provincial science and technology progress awards in the past three years, including 6 first prizes [1] Group 3: Talent High Ground - The province boasts 2 academicians, 4 national TCM masters, 8 renowned TCM practitioners, 188 national-level TCM talents, and over 300 provincial-level TCM practitioners, with a TCM general practitioner ratio of 0.93 per 10,000 people [1] Group 4: Industry High Ground - 22 varieties of southern medicine have been recognized as national special and superior new agricultural products, with 4 national-level and 18 provincial-level southern medicine industrial parks established. The revenue of the large-scale TCM industry is expected to reach 65.559 billion yuan in 2024 [1] Group 5: International Cooperation High Ground - The Guangdong-Hong Kong-Macao Greater Bay Area TCM inheritance and innovation development conference has been organized, facilitating high-quality exchange and cooperation, with over 50,000 bottles of 9 varieties of hospital preparations cross-border dispensed to Macau [2] - A total of 24 traditional Chinese medicine products have completed international registration and filing through the Guangdong-Macao cooperation TCM technology industrial park [2] Group 6: Management and Talent Reform - All cities and 95% of counties (districts) have established TCM management institutions, with 5 secondary and above public comprehensive hospitals transformed into TCM hospitals, optimizing the layout of TCM medical institutions [2] - A total of 4,865 senior professional titles have been approved since the implementation of the talent evaluation system, with 61 individuals obtaining provincial-level senior titles in the past three years [2] Group 7: Drug Approval and Insurance Mechanism - Guangdong has reformed the drug review and approval system, promoting the integration of TCM in the Greater Bay Area, with the establishment of an expert committee for TCM standards and the release of 7 TCM standards [3] - A total of 1,336 traditional Chinese medicine products, 1,655 TCM decoction pieces, and 136 traditional TCM diagnostic and treatment projects have been included in the medical insurance payment scope by 2025 [3]

Group 1 - The second China Respiratory Health Conference opened in Guangzhou, focusing on "Collaborative Innovation of Traditional and Western Medicine: Building a New Pattern of Respiratory Health" with over 2,000 experts and scholars in attendance [1] - The "2026 Respiratory Health Community" was established during the opening ceremony, with Tianyao Darentang being one of the first member units [3] - Tianyao Darentang, a traditional Chinese medicine company with a 500-year history, has a product portfolio of 599 drug approvals, including 122 exclusive varieties, covering various health areas [4] Group 2 - In the respiratory product line, Tianyao Darentang has 102 varieties, showcasing key products such as Qingyan Diban and Qingfei Xiaoyan Wan at the conference [5] - The company aims to protect and develop traditional Chinese medicine while promoting respiratory health, focusing on collaboration within the community to enhance innovation [5]

Core Insights - The article highlights the progress and achievements of Dongying City in the development of traditional Chinese medicine (TCM) in alignment with national and provincial policies [1][5]. Group 1: Reform and Development - Dongying has established a monthly monitoring mechanism for high-quality TCM development indicators, enhancing the management and performance of public TCM hospitals [3]. - Several projects from Dongying have been selected as provincial and national pilot projects, including the "Information Technology Leading and Supporting High-Quality Development of TCM" project, which has been recognized by the National Administration of Traditional Chinese Medicine [1][3]. Group 2: Service Capacity and Accessibility - A total of 117 visits by expert TCM practitioners have been conducted since April, resulting in 1,348 prescriptions for traditional Chinese medicine pieces and 643 prescriptions for granules, significantly improving service capacity [3]. - All village clinics and community health service stations in Dongying now provide TCM services, expanding accessibility through the promotion of specialized therapies and suitable techniques [3]. Group 3: Cultural Promotion and Community Engagement - Dongying has established a provincial-level TCM cultural promotion and education base and has conducted various community health initiatives, serving over 26,000 people throughout the year [4]. - The city has implemented an integrated TCM diagnosis and treatment regulatory system, allowing real-time data collection and analysis across four levels of medical institutions [4]. Group 4: Future Directions - Dongying plans to continue deepening TCM reform and innovation, accelerating digital transformation, and promoting high-quality TCM services to contribute to the health development of the city [5].

Group 1: Overview of Traditional Chinese Medicine (TCM) Development in Zhejiang - Zhejiang is a major province for traditional Chinese medicine, with 4,599 TCM medical institutions, including 49 tertiary public TCM hospitals, ranking second in the country [1] - By 2024, total outpatient visits in public TCM hospitals are expected to reach 61.83 million, with inpatient discharges projected at 1.76 million [1] - Hangzhou has implemented a "smart TCM" initiative, enhancing healthcare services through technology, including a "smart tongue diagnosis" platform that has served over one million people [1] Group 2: Healthcare Policy and Insurance Support - Hangzhou's Medical Security Bureau has added 17 new TCM service projects and adjusted prices for 99 existing projects to optimize insurance payments for the public [2] - A dynamic pricing mechanism for TCM herbal pieces and formulations has been established to ensure reasonable pricing and quality assurance [2] - The city has initiated traceability management for TCM herbal pieces, with two batches of 15 medicinal materials undergoing traceability work, four of which are nearing clinical application [2] Group 3: Integration of TCM with Lifestyle and Tourism - TCM tea drinks and markets are gaining popularity, with Hangzhou focusing on creating engaging cultural and tourism experiences around TCM [2] - Notable initiatives include the introduction of "Chinese medicine coffee" and seasonal health activities that attract significant tourist engagement [2] - The city has hosted over 300 TCM-themed cultural markets, integrating health services, heritage experiences, and creative product sales, with events attracting up to 30,000 visitors in a single night [3]